Novartis to respond to US senator over Zolgensma scandal

Monday, 19. August 2019 12:18

Swiss pharmaceutical giant Novartis International AG will provide details to US Senator Chuck Grassley about its data manipulation relating to Zolgensma, the company said on Monday.

"We are planning to respond but we haven’t submitted yet," a spokesman said. Earlier this month, the US Food and Drug Administration revealed that Novartis knew its application for its gene therapy contained errors.​

Grassley, who heads the Senate Finance Committee, asked the drugmaker to submit details from the early testing of Zolgensma, the world's most expensive treatment.

Related Links: Novartis AG
Breaking the News / JC